US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known as SPG302), a synaptic regenerative treatment for ...

Antipsychotic medicines are a key part of the pharmacological treatment of schizophrenia. Although they provide therapeutic ...

UCSF researcher Daniel Mathalon, MD, PhD, believes that burgeoning knowledge about biomarkers — biological measures of a ...

Other cells, such as glial cells, support the function of neurons. Neuroscience has often painted glial cells as the glue that holds neurons together, but glial cells can also be helpful in promoting ...

Using proprietary copolymer technology, TEV-’749 allows for a controlled steady release of olanzapine, a second generation antipsychotic.

MADRID — Virtual reality (VR)–based cognitive behavioral therapy (CBT) may be an alternative treatment option for patients with paranoia based on results of a new randomized, controlled trial. The ...

A University of Kentucky researcher is leading a team in what the university calls a groundbreaking study. According to UK, the study identifies biological markers for schizophrenia, which could ...

Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.

For over a hundred years, the specter of a schizophrenia diagnosis has frightened patients and their families. Yet it confers no useful meaning for treatment or prognosis.

THURSDAY, Sept. 4, 2025 (HealthDay News) -- Initiating cannabis use for self-medication is associated with higher weekly use and increased anxiety, depression, and paranoia, according to a study ...